Aliskiren versus irbesartan and ramipril after a missed dose in essential hypertension

Phase 3, randomised, double-blind trial in essential hypertension comparing Aliskiren arm, Irbesartan arm and Ramipril arm (3 arms). Primary endpoints: Change from baseline in mean ambulatory 24-hour diastolic blood pressure and Change from baseline in mean ambulatory 24-hour systolic blood pressure. Started Mar 2006; status: completed.